Our Team

The Medical Advisory Board provides guidance on the best childhood cancer researchers in the country who are working everyday to open new paths to find a cure. In addition, the Advisory Board for TeamConnor are dedicated professionals who believe they can make a difference in this battle to find a cure for childhood cancer by offering their talent and resources for the cause.

Chrystal Louis, MD
Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Texas Children’s Hospital

Dr. Chyrstal Louis is an assistant professor of Pediatrics at the Baylor College of Medicine. She is a member of the translational research laboratory in the Center for Cell and Gene Therapy. Currently, she has been working on methods to improve immunotherapy options for patients with solid tumors. She has also focused her research on therapeutic strategies for patients with either nasopharyngeal carcinoma (NPC) or neuroblastoma.

Dr. Louis earned her MD at Tulane University School of Medicine and her MPH at Tulane University School of Public Health and Tropical Medicine. She completed her residency at the University of California at Davis and a fellowship at Baylor College of Medicine.
Ira Dunkel, MD
Pediatric Oncologist
Memorial Sloan-Kettering Cancer Center

Dr. Ira Dunkel is a board certified pediatric oncologist specializing in brain and eye tumors, including medulloblastoma and retinoblastoma. In his clinical research, he and his colleagues are exploring a new treatment regimen for patients with medulloblastoma that is intended to reduce side effects by limiting the amount of radiation given to areas of the brain without cancer. He is also working to develop new treatments for retinoblastoma.

Dr. Dunkel earned his MD at Duke University School of Medicine. He completed his residency at the Duke University Medical Center, as well as a fellowship at Duke University and Memorial Sloan-Kettering Cancer Center.
Joya Chandra, Ph.D.
Associate Professor of Pediatrics Research
Children’s Cancer Hospital at M.D. Anderson

Dr. Joya Chandra, associate professor in the Division of Pediatrics at The University of Texas MD Anderson Cancer Center in Houston, TX, specializes in the study of the oxidative environments of cancer cells and therapeutic strategies that eliminate cancer cells. She serves as a lecturer for The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS) in Cancer Cell Signaling and Mechanisms in Cancer Therapeutics.

Dr. Chandra received her Ph.D. in cancer biology and immunology from the GSBS. She completed a postdoctoral fellowship in apoptosis and oxidative stress in the Division of Toxicology, Institute for Environmental Medicine at the Karolinska Institute.
Kate Matthay, MD
Professor, Department of Pediatrics, and Division Chief, University of California Benioff Children’s Hospital San Francisco

Dr. Katherine Matthay, chief of pediatric hemotology/oncology, is one of the world’s leading doctors and researchers in treatments for childhood cancer. She directs a national study of the Children’s Oncology Group to test new therapies for neuroblastoma. She and her colleagues demonstrated that the outcome of neuroblastoma can be significantly improved by the use of innovative treatment the includes chemotherapy, bone marrow transplant, and the vitamin A derivative, 13-cis-retinoic acid.

Dr. Matthay earned an undergraduate degree in chemistry at Bryn Mawr College in Pennsylvania and a medical degree at the University of Pennsylvania in Philadelphia. She completed a residency in pediatrics at the University of Colorado in Denver and a fellowship in pediatric hematology and oncology at UCSF Medical Center.
Meaghan Granger, MD
Hematology/Oncology Physician
Cooks Children’s Medical Center

Dr. Granger is a pediatric physician at the Cook Children’s Hematology and Oncology Center specializing in bone marrow and stem cell transplant and neuroblastoma. She is a neuroblastoma researcher, participating in clinical trial investigations of existing and new treatments for neuroblastoma, an important step in the development of new treatments.

Dr. Granger earned her MD at the University of Arkansas for Medical Sciences. She completed a residency at Vanderbilt University and a fellowship at Children’s Memorial, Chicago, IL and at Children’s Medical Center of Dallas, TX in both hematology and oncology.
Mignon Loh, MD
Professor of Clinical Pediatrics
University of California Benioff Children’s Hospital San Francisco

Dr. Mignon Loh, an assistant clinical professor of pediatrics at UCSF, is a pediatric cancer specialist with a particular interest in the treatment of children with leukemia, lymphoma and sarcomas. Her research broadly involves the identification, significance, and function of genetic mutations in pediatric leukemia. Dr. Loh has focused on integrating novel mutations into clinical use (e.g. assessing prognostic significance or minimal residual disease) as well as yield insights that lead to more scientific questions about the pathogenesis and mechanisms of disease.

She earned a bachelor's degree at Bryn Mawr College in Pennsylvania and a medical degree at Columbia University. She served as an instructor at Harvard Medical School and as a research fellow at Brigham and Women's Hospital in Boston. She joined UCSF as an associate professor in 2006.
Sarah Tasian, MD
Assistant Professor and Physician Scientist
Children’s Hospital of Philadelphia

Sarah K Tasian, MD is an assistant profession and physician scientist of pediatric hematology/oncology at Children's Hospital of Philadelphia. Previously, she was pediatric hematology/oncology fellow at the University of California, San Francisco, where she studied acute lymphoblastic leukemia in the lab of Dr. Mignon Loh and cared for children with cancer and blood disorders. She has focused upon optimization of phosphoflow techniques in human cell lines to determine important intracellur signaling molecules and pathways in B-precursor ALL, the most common childhood cancer.

Dr. Tasian attended Baylor College of Medicine and spent a year in Bethesda, Maryland, at the National Institutes of Health/National Cancer Institute, Pediatric Oncology Branch investigating dendritic cell-based tumor immunotherapy. She completed her pediatrics residency at Seattle Children’s Hospital/University of Washington, and is a board-certified pediatrician.
Winston W. Huh, MD
Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics
The University of Texas MD Anderson Cancer Center

Dr. Winston W. Huh is an assistant professor in the Department of Pediatrics Patient Care at The University of Texas MD Anderson Cancer Center in Houston, TX. His research interests include osteosarcoma of the jaw in children and young adults and gastric adenocarcinoma, an extremely rare cancer in children with very limited information on the clinical presentation and outcome.

Dr. Huh earned his MD at the University of Kentucky School Of Medicine. He completed his residency in pediatrics at the Children’s Medical Center in Dallas, TX and became Chief Resident the following year.

Our Featured Hero

Ashley Piltz

Ashley Piltz

Our world completely changed on September 12, 2007..

Read More

Did You Know

Building awareness of childhood cancer is critical to funding and finding a cure. To help, please consider sharing teamconnor.org on your Facebook.

Today, 46 children will be diagnosed with cancer.  Seven will lose their battle.

Did you know September is National Childhood Cancer Awareness Month!

Every day in America, approximately 46 children are diagnosed with cancer.

Childhood cancer does not discriminate, sparing no ethnic group, socio-economic class, or geographic region.

Rhabdomyosarcoma is the most common soft tissue sarcoma in children, accounting for about 3% of childhood cancers.

On average, 1 in every 4 elementary schools has a child with cancer.

About one-third of childhood cancers are leukemias.

Childhood cancer survival rates in the United States have increased from less than 20% in the 1960s to almost 80% today.

Cancer kills more children each year than Asthma, Cystic Fibrosis, Diabetes, and Pediatric AIDS combined.

Childhood cancer is not one disease entity, but rather a spectrum of different malignancies. Cancers found in children are biologically different from those seen in adults.

1 in 300 children will develop cancer before age 20.

Neuroblastoma is the most common extra cranial solid tumor cancer in children.

Today, up to 75% of the children with cancer can be cured, yet, some forms of childhood cancers have proven so resistant to treatment that, in spite of research, a cure is illusive.

Sign up to comment in the forums, on posts, and receive our newsletters.

Your Email Address
Sign Up